ArticleGlobal cardiology science & practice2014
Genetic susceptibility to endomyocardial fibrosis.
Article in Global cardiology science & practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 27 citations in OpenAlex.
- A Narrative Review on Endomyocardial Fibrosis: Unraveling an Under-Recognized Tropical Heart Disease.Cureus · 2025Review
- Endomyocardial fibrosis: recent advances and future therapeutic targets.Nature reviews. Cardiology · 2025Review
- Cardiac Abnormalities in Hypereosinophilic Syndromes.Arquivos brasileiros de cardiologia · 2024Review
- An unusual tropical endomyocardial fibrosis: a case report.The Pan African medical journal · 2022Article
- Cardiovascular diseases in Africa in the twenty-first century: Gaps and priorities going forward.Frontiers in cardiovascular medicine · 2022Review
- Idiopathic endomyocardial fibrosis in a Western European: a case report.European heart journal. Case reports · 2020Article
- Challenges in addressing the knowledge gap on endomyocardial fibrosis through community-based studies.Cardiovascular diagnosis and therapy · 2020Review
- Article
- Endomyocardial Fibrosis: an Update After 70 Years.Current cardiology reports · 2019Review
- Feasibility of south-south collaboration in Africa: the Uganda-Mozambique perspective.Cardiovascular journal of AfricaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndomyocardial fibrosis (EMF) is the most common form of restrictive cardiomyopathy worldwide. It has been linked to poverty and various environmental factors, but-for unknown reasons-only some people who live in similar conditions develop the disease. EMF cases cluster within both families and ethnic groups, suggesting a role for a genetic factor in host susceptibility. The human leukocyte antigen (HLA) system is associated with predisposition to various diseases. This two-center study was designed to investigate variation in the HLA system between EMF patients and unaffected controls. We provide the first genetic investigation of patients with EMF, as well as a comprehensive review of the literature.
methodsHLA class I (HLA-A, -B, -C) and class II (DRB1, DQB1) types were determined in 71 patients with severe EMF and 137 controls from Uganda and Mozambique. Chi Square analysis was used to identify any significant difference in frequency of class I and class II HLA types between cases and controls.
resultsCompared to ethnically matched controls, HLA-B*58 occurred more frequently in Mozambique patients with EMF and HLA-A*02:02 occurred more frequently in Ugandan patients with EMF.
conclusionsAmple subjective evidence in the historical literature suggests the importance of a genetically susceptible host in EMF development. In this first formal genetic study, we found HLA alleles associated with cases of EMF in two populations from sub-Saharan Africa, with EMF patients being more likely than controls to have the HLA-B*58 allele in Mozambique (p-0.03) and the HLA-A*02:02 in Uganda (p = 0.005). Further investigations are needed to more fully understand the role of genetics in EMF development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.